Glofitamab for Relapsed or Refractory Diffuse Large B-Cell LymphomaMichael Dickinson, Martin Hutchings, Paolo Corradini et al.|New England Journal of Medicine|2022Cited by 718
Glofitamab Step-up Dosing Induces High Response Rates in Patients with Hard-to-Treat Refractory or Relapsed Non-Hodgkin LymphomaMartin Hutchings, Michael Dickinson, Carmelo Carlo‐Stella et al.|Blood|2020Cited by 56